JP2005533751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533751A5 JP2005533751A5 JP2003577859A JP2003577859A JP2005533751A5 JP 2005533751 A5 JP2005533751 A5 JP 2005533751A5 JP 2003577859 A JP2003577859 A JP 2003577859A JP 2003577859 A JP2003577859 A JP 2003577859A JP 2005533751 A5 JP2005533751 A5 JP 2005533751A5
- Authority
- JP
- Japan
- Prior art keywords
- donating
- drug delivery
- delivery composition
- solid drug
- porous particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 46
- 239000002245 particle Substances 0.000 claims description 41
- 238000012377 drug delivery Methods 0.000 claims description 35
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 34
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 34
- 239000004094 surface-active agent Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 34
- 238000004519 manufacturing process Methods 0.000 claims 8
- 229960001259 diclofenac Drugs 0.000 claims 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 4
- 238000003756 stirring Methods 0.000 claims 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 3
- 229960000991 ketoprofen Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229960002009 naproxen Drugs 0.000 claims 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 3
- -1 polyoxyethylene Polymers 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 229920001400 block copolymer Polymers 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims 1
- CLFSHUKVMLTNAV-UHFFFAOYSA-N 3-nitrooxypropyl 2-(3-benzoylphenyl)propanoate Chemical compound [O-][N+](=O)OCCCOC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 CLFSHUKVMLTNAV-UHFFFAOYSA-N 0.000 claims 1
- CQVHWLHWUZRTQC-UHFFFAOYSA-N 4-nitrooxybutyl 2-[2-(2,6-dichloroanilino)phenyl]acetate Chemical compound [O-][N+](=O)OCCCCOC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl CQVHWLHWUZRTQC-UHFFFAOYSA-N 0.000 claims 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- 229940121819 ATPase inhibitor Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- BLGCOWFCUDFELQ-UHFFFAOYSA-N [4-(nitrooxymethyl)phenyl]methyl 2-(3-benzoylphenyl)propanoate Chemical compound C=1C=CC(C(=O)C=2C=CC=CC=2)=CC=1C(C)C(=O)OCC1=CC=C(CO[N+]([O-])=O)C=C1 BLGCOWFCUDFELQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229960004770 esomeprazole Drugs 0.000 claims 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 229960003174 lansoprazole Drugs 0.000 claims 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 1
- 229950007395 leminoprazole Drugs 0.000 claims 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229960004157 rabeprazole Drugs 0.000 claims 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229920002023 Pluronic® F 87 Polymers 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 229920002511 Poloxamer 237 Polymers 0.000 description 1
- 229920002517 Poloxamer 338 Polymers 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000010436 fluorite Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200895A SE0200895D0 (sv) | 2002-03-22 | 2002-03-22 | New pharmaceutical composition |
| PCT/SE2003/000468 WO2003080029A1 (en) | 2002-03-22 | 2003-03-20 | No-donating nsaids adsorbed into carrier particles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010171855A Division JP2010285445A (ja) | 2002-03-22 | 2010-07-30 | 担体粒子に吸着されたｎｏ−供与ｎｓａｉｄ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533751A JP2005533751A (ja) | 2005-11-10 |
| JP2005533751A5 true JP2005533751A5 (https=) | 2010-12-02 |
Family
ID=20287374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577859A Withdrawn JP2005533751A (ja) | 2002-03-22 | 2003-03-20 | 担体粒子に吸着されたｎｏ−供与ｎｓａｉｄ |
| JP2010171855A Abandoned JP2010285445A (ja) | 2002-03-22 | 2010-07-30 | 担体粒子に吸着されたｎｏ−供与ｎｓａｉｄ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010171855A Abandoned JP2010285445A (ja) | 2002-03-22 | 2010-07-30 | 担体粒子に吸着されたｎｏ−供与ｎｓａｉｄ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050129774A1 (https=) |
| EP (1) | EP1490033A1 (https=) |
| JP (2) | JP2005533751A (https=) |
| AR (1) | AR038951A1 (https=) |
| AU (1) | AU2003216006A1 (https=) |
| SE (1) | SE0200895D0 (https=) |
| TW (1) | TW200307564A (https=) |
| UY (1) | UY27727A1 (https=) |
| WO (1) | WO2003080029A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
| IT1319202B1 (it) | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per le malattie a base infiammatoria. |
| ITMI20021392A1 (it) * | 2002-06-25 | 2003-12-29 | Nicox Sa | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' |
| EP1534278A4 (en) | 2002-08-01 | 2006-09-06 | Nitromed Inc | NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD |
| PT1578422E (pt) | 2002-12-20 | 2007-06-14 | Niconovum Ab | Material particulado contendo nicotina fisicamente e quimicamente estável |
| SE0301880D0 (sv) * | 2003-06-25 | 2003-06-25 | Astrazeneca Uk Ltd | New drug delivery composition |
| TW200533374A (en) * | 2003-11-13 | 2005-10-16 | Alza Corp | Melt blend dispersions |
| AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
| US20100221337A1 (en) * | 2007-02-14 | 2010-09-02 | Logical Therapeutics, Inc. | Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist |
| WO2009012425A2 (en) * | 2007-07-19 | 2009-01-22 | Logigal Therapeutics, Inc. | Compositions including leukotriene antagonists and nsaids and methods of using the same |
| WO2009149053A2 (en) * | 2008-06-02 | 2009-12-10 | Dr. Reddy's Laboratories Ltd. | Naproxcinod process and solid dispersion |
| CA2736531C (en) * | 2008-09-17 | 2016-10-25 | Modoral Brands Inc. | Process for preparing snuff composition |
| DE102010052847A1 (de) | 2010-11-29 | 2012-05-31 | Temmler Werke Gmbh | Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung |
| WO2015040212A1 (en) * | 2013-09-20 | 2015-03-26 | Tillotts Pharma Ag | Delayed release pharmaceutical formulation |
| WO2016080336A1 (ja) | 2014-11-18 | 2016-05-26 | 国立研究開発法人物質・材料研究機構 | 多孔性粒子の製造方法 |
| GB201502077D0 (en) * | 2015-02-09 | 2015-03-25 | Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd | Improved hme technology |
| GB201502073D0 (en) | 2015-02-09 | 2015-03-25 | Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd | HDEG technology |
| CN119486717A (zh) * | 2022-04-29 | 2025-02-18 | 曼金德公司 | 治疗肺疾病的方法和组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2700141B2 (ja) * | 1993-09-17 | 1998-01-19 | 富士化学工業株式会社 | リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤 |
| JPH08301763A (ja) * | 1995-04-28 | 1996-11-19 | Dainippon Pharmaceut Co Ltd | 易溶性粉末状医薬組成物およびその製造方法 |
| KR100618234B1 (ko) * | 1998-12-23 | 2006-09-01 | 알자 코포레이션 | 다공성 입자를 포함하는 제형 |
| CA2372994C (en) * | 1999-06-04 | 2010-03-23 | Alza Corporation | Implantable gel compositions and method of manufacture |
| US6793934B1 (en) * | 1999-12-08 | 2004-09-21 | Shire Laboratories, Inc. | Solid oral dosage form |
| JP2001316248A (ja) * | 2000-02-28 | 2001-11-13 | Eisai Co Ltd | 油状薬物含有組成物の製造方法 |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| ITMI20021392A1 (it) * | 2002-06-25 | 2003-12-29 | Nicox Sa | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' |
-
2002
- 2002-03-22 SE SE0200895A patent/SE0200895D0/xx unknown
-
2003
- 2003-03-12 AR ARP030100860A patent/AR038951A1/es not_active Application Discontinuation
- 2003-03-20 EP EP03745055A patent/EP1490033A1/en not_active Withdrawn
- 2003-03-20 US US10/507,368 patent/US20050129774A1/en not_active Abandoned
- 2003-03-20 JP JP2003577859A patent/JP2005533751A/ja not_active Withdrawn
- 2003-03-20 AU AU2003216006A patent/AU2003216006A1/en not_active Abandoned
- 2003-03-20 UY UY27727A patent/UY27727A1/es not_active Application Discontinuation
- 2003-03-20 WO PCT/SE2003/000468 patent/WO2003080029A1/en not_active Ceased
- 2003-03-20 TW TW092106166A patent/TW200307564A/zh unknown
-
2010
- 2010-07-30 JP JP2010171855A patent/JP2010285445A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533751A5 (https=) | ||
| RU2170090C2 (ru) | Способ получения фармацевтической лекарственной формы, способ ингибирования секреции кислоты в желудке у млекопитающих и человека | |
| RU2158138C2 (ru) | Фармацевтические лекарственные формы для перорального приема, содержащие ингибитор протонного насоса и средство нестероидной противовоспалительной терапии | |
| JP2010285445A (ja) | 担体粒子に吸着されたｎｏ−供与ｎｓａｉｄ | |
| EP1521574B1 (fr) | Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation | |
| JP5714492B2 (ja) | 粒状体、それらの調製方法、およびそれらを含む医薬品 | |
| US20230240994A1 (en) | Medicament-containing hollow particle | |
| ES2246238T3 (es) | Nueva preparacion y forma de administracion que comprende un inhibidor de las bombas de protones labil en medio acido. | |
| UA69396C2 (uk) | ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА З ДИСКРЕТНИМ ВИВІЛЬНЕННЯМ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ (ВАРІАНТИ) ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (ВАРІАНТИ) І СПОСІБ ЛІКУВАННЯ (ВАРІАНТИ) | |
| JPH09511767A (ja) | 新規な経口用の医薬使用形態 | |
| JP2005530835A (ja) | 改良された生物学的利用能を有する液体薬剤の経口医薬形態 | |
| UA69397C2 (uk) | ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА ПОДОВЖЕНОЇ ДІЇ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА СПОСІБ ЛІКУВАННЯ | |
| WO2007103453A1 (en) | Ezetimibe compositions | |
| RU2007126652A (ru) | Композиции и способы стабилизации активных фармацевтических ингредиентов | |
| JP2006528221A5 (https=) | ||
| JP2004514733A (ja) | 酸分解性活性成分を含有するペースト形の医薬品製造物 | |
| JP6160263B2 (ja) | ロキソプロフェン含有医薬組成物 | |
| TW201211025A (en) | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists | |
| CN1135981C (zh) | 硫酸吗啡微粒、其制备方法和药物制剂 | |
| JPWO2007074910A1 (ja) | 放出制御固形製剤 | |
| JP3909998B2 (ja) | 経口投与製剤 | |
| JPH0635383B2 (ja) | ケトプロフエンの経口投与のための放出が制御された錠剤及びその製造方法 | |
| TW201016210A (en) | Galenical formulations of organic compounds | |
| CA2591983A1 (en) | Pharmaceutical compositions comprising amorphous benzimidazole compounds | |
| UA12297U (en) | Matrix tablet providing for delayed release of trimetasin |